1. A 58-year-old man with treatment-resistant depression and a longstanding history of hypertension presents for his scheduled esketamine nasal spray administration. He ran out of his antihypertensive medications four days ago and has not been able to refill them. His pre-administration blood pressure today is 172/104 mmHg. He is otherwise alert, without headache, visual changes, or chest pain. The clinic nurse pages you for guidance. What is the most appropriate course of action?
A) Proceed with esketamine administration at the full prescribed dose of 84 mg because sympathomimetic blood pressure elevation from esketamine is mild and self-limiting at antidepressant doses and will not produce clinically meaningful additional hypertension in this patient
B) Defer esketamine administration until blood pressure is better controlled; uncontrolled hypertension at this level represents a relative contraindication requiring pre-treatment optimization before safe esketamine administration can proceed, given that esketamine produces additional sympathomimetic blood pressure elevation through catecholamine reuptake inhibition
C) Proceed with esketamine at a reduced dose of 28 mg, because halving the dose will proportionally reduce the sympathomimetic cardiovascular effect while still delivering a therapeutic intranasal esketamine exposure
D) Administer IV labetalol 20 mg immediately to lower blood pressure to below 140/90 mmHg, then proceed with full-dose esketamine within the same clinic visit once the target blood pressure is achieved
E) Proceed with esketamine administration as scheduled but arrange for continuous arterial line monitoring during the session to detect any further blood pressure elevation and respond with intravenous antihypertensive medication if needed
ANSWER: B
Rationale:
Uncontrolled or severe hypertension is a recognized relative contraindication to both esketamine and IV ketamine in the antidepressant setting. Esketamine produces sympathomimetic cardiovascular effects through inhibition of catecholamine reuptake, generating transient increases in systolic blood pressure of approximately 10 to 20 mmHg and diastolic blood pressure of approximately 5 to 15 mmHg above the pre-administration baseline. In a patient whose baseline blood pressure is already 172/104 mmHg, these additional elevations could bring systolic pressure into a range exceeding 190 mmHg, creating meaningful risk for hypertensive urgency or, in susceptible patients, end-organ events. The appropriate clinical response is to defer treatment, contact the patient's prescriber or primary care physician to expedite antihypertensive medication refill, and reschedule esketamine once blood pressure is adequately controlled. This protects the patient from compounded hypertensive risk while maintaining access to treatment once the correctable barrier is resolved.
Option A: Option A is incorrect because the characterization of esketamine's cardiovascular effects as clinically trivial does not apply to a patient with a pre-administration blood pressure of 172/104 mmHg. At this baseline, additive sympathomimetic elevation places the patient at meaningful cardiovascular risk. The self-limiting nature of the pressor effect does not eliminate the clinical concern when the starting blood pressure is already in the severe range.
Option C: Option C is incorrect because administering a reduced dose of 28 mg is not a validated strategy for managing pre-existing hypertension. The 28 mg actuation is the unit delivery of the device, not a recognized lower therapeutic dose, and administering a subtherapeutic dose exposes the patient to adverse effects without providing reliable antidepressant efficacy.
Option D: Option D is incorrect because administering IV labetalol and proceeding with esketamine during the same visit is not the appropriate management strategy. Acute pharmacological blood pressure reduction immediately before esketamine in an outpatient or clinic setting raises its own safety concerns, and the same-visit proceed plan does not allow adequate time to assess the stability and adequacy of the blood pressure response before exposing the patient to the esketamine-associated pressor effect.
Option E: Option E is incorrect because arterial line monitoring is not appropriate or available in an outpatient esketamine clinic setting, and proceeding with administration in the presence of uncontrolled severe hypertension does not become acceptable simply because monitoring intensity is increased. The correct action is deferral, not monitored administration at elevated cardiovascular risk.
2. A 44-year-old woman with treatment-resistant depression has been receiving esketamine nasal spray for eight weeks with good antidepressant response. She asks her psychiatrist why she cannot simply pick up the medication at a pharmacy and administer it at home, particularly since she feels she has tolerated it well and knows what to expect. She notes that she takes other controlled substances at home without clinic supervision. What is the most accurate explanation for the clinic-administration requirement?
A) The clinic-administration requirement exists because esketamine must be mixed with a diluent solution immediately before use; this preparation step requires pharmaceutical training and sterile technique that cannot safely be performed by patients at home
B) Esketamine cannot be dispensed through a pharmacy because it has not yet received standard DEA scheduling; until scheduling is finalized, it can only be distributed through certified healthcare facilities under investigational new drug protocols
C) The requirement exists because esketamine is chemically unstable at room temperature and must be stored in medical-grade refrigeration units maintained at 2 to 8 degrees Celsius that are not available in home settings
D) The Risk Evaluation and Mitigation Strategy program requires clinic-based administration because esketamine reliably produces dissociative symptoms and transient blood pressure elevation with each dose, creates sedation that impairs safe driving, and carries abuse potential as a Schedule III controlled substance — risks that require trained clinical observation, vital sign monitoring, a mandatory two-hour observation period, and a confirmed transportation plan that cannot be replicated in an unsupervised home setting
E) The clinic-administration requirement applies only to the induction phase of treatment; once a patient has completed the full induction schedule and achieved stable response, the Risk Evaluation and Mitigation Strategy (REMS) program permits home administration under a remote monitoring protocol with telehealth check-ins
ANSWER: D
Rationale:
The REMS program for esketamine requires administration in a certified healthcare setting for pharmacodynamic, safety, and regulatory reasons that collectively cannot be replicated in an unsupervised home environment. With each administration, esketamine produces dissociative symptoms and perceptual alterations requiring clinical observation to ensure patient safety and detect any adverse behavioral responses; transient sympathomimetic blood pressure elevation requiring vital sign monitoring at 15-minute intervals to detect hypertensive responses warranting intervention; sedation that persists for several hours and prohibits driving on the day of treatment, necessitating a confirmed transportation plan and a minimum two-hour monitored observation period before the patient is cleared for discharge; and Schedule III controlled substance status reflecting established misuse and psychological dependence potential at higher doses, which the REMS program addresses by prohibiting take-home dispensing entirely. The patient's tolerance of prior administrations does not eliminate these pharmacodynamic risks, which recur with every dose, and prior experience with other home-administered controlled substances does not confer equivalence to a drug with esketamine's acute dissociative and cardiovascular profile.
Option A: Option A is incorrect because esketamine nasal spray (Spravato) is a prefilled nasal spray device that does not require pharmacist preparation or mixing at the point of use. The device is ready to use and does not require sterile technique or compounding.
Option B: Option B is incorrect because esketamine is a federally scheduled controlled substance — Schedule III — under the Controlled Substances Act. Its restricted distribution is governed by the REMS program requirements, not by a pending scheduling determination.
Option C: Option C is incorrect because esketamine nasal spray does not require medical-grade refrigeration at 2 to 8 degrees Celsius. The product is stored at room temperature. The administration restriction is pharmacodynamic and regulatory, not related to cold-chain storage requirements.
Option E: Option E is incorrect because the REMS program does not permit home administration at any phase of treatment, including maintenance. The clinic-administration and monitoring requirements apply to every dose throughout the treatment course, including induction and all maintenance administrations.
3. A 36-year-old man carries a longstanding diagnosis of schizoaffective disorder, depressive type, and is currently stable on a clozapine regimen with no psychotic symptoms for the past 14 months. He now presents with a severe depressive episode that has not responded to two adequate trials of antidepressant augmentation. His outpatient psychiatrist refers him for consideration of esketamine therapy. Which is the most appropriate clinical determination regarding esketamine candidacy in this patient?
A) Schizoaffective disorder is a clinical contraindication to esketamine because NMDA receptor blockade produces dissociative and psychotomimetic effects that risk precipitating a psychotic episode or destabilizing the underlying psychotic disorder even in a patient who is currently psychiatrically stable, and the risk-benefit assessment in a patient with an active psychotic disorder diagnosis does not support esketamine use
B) The patient is an appropriate candidate for esketamine because his schizoaffective disorder is currently well-controlled on clozapine, and stable psychiatric status at the time of treatment eliminates the psychosis risk associated with NMDA blockade for the duration of treatment
C) The patient is an appropriate candidate because clozapine's potent D2 and 5-HT2A receptor blockade will pharmacodynamically neutralize esketamine's psychotomimetic effects, making the combination safer in patients with psychotic disorders than esketamine alone
D) The patient should receive esketamine at half the standard dose with an additional clozapine dose administered 30 minutes before each esketamine session to provide pharmacodynamic cover against NMDA-related psychosis precipitation
E) The contraindication to esketamine in psychotic disorders applies only to patients who are unmedicated; patients stabilized on an antipsychotic with D2 blocking activity are categorically safe to receive esketamine because dopaminergic blockade prevents the dopamine dysregulation that mediates ketamine-induced psychosis
ANSWER: A
Rationale:
Active psychotic disorders, including schizophrenia and schizoaffective disorder, represent a clinical contraindication to esketamine regardless of current symptom stability. The pharmacological basis is that NMDA receptor blockade produces dissociative and psychotomimetic effects — perceptual distortions, derealization, depersonalization, and in susceptible individuals psychosis-like experiences — that can destabilize a patient with an underlying psychotic disorder even when they are currently asymptomatic. The glutamate hypothesis of schizophrenia posits that NMDA receptor hypofunction is a core pathological feature; administering an NMDA antagonist superimposes pharmacological hypofunction on an already dysregulated glutamatergic system, creating meaningful risk of psychotic relapse. Current psychiatric stability on clozapine does not eliminate this risk because the risk arises from the pharmacodynamic interaction between NMDA blockade and the vulnerability conferred by the underlying diagnosis, not from the current severity of symptoms. Referring the patient back to his treatment team to explore alternative augmentation strategies for treatment-resistant depressive episodes within schizoaffective disorder is the appropriate response.
Option B: Option B is incorrect because current symptom stability does not eliminate the risk of NMDA antagonist-induced psychosis precipitation in a patient with schizoaffective disorder. The clinical contraindication is based on the pharmacological vulnerability conferred by the diagnosis, not on the current symptom state. A patient who is asymptomatic today can experience a psychotic episode triggered by NMDA blockade.
Option C: Option C is incorrect because clozapine's D2 and 5-HT2A blockade does not provide pharmacodynamic neutralization of esketamine's psychotomimetic effects. Ketamine's psychotomimetic effects are mediated primarily through NMDA receptor blockade and downstream glutamatergic circuit destabilization, not through dopaminergic mechanisms that would be blocked by clozapine. The two drugs act on different receptor systems, and clozapine's receptor profile does not confer safety against NMDA antagonist-induced psychosis.
Option D: Option D is incorrect because there is no validated protocol for using half-dose esketamine with pre-treatment clozapine supplementation in patients with schizoaffective disorder, and this approach would expose the patient to esketamine's psychotomimetic risks without established evidence of safety in this population. The clinical contraindication is not mitigated by dose reduction or pre-medication strategies of this kind.
Option E: Option E is incorrect because the contraindication is not limited to unmedicated patients. Antipsychotic treatment reduces psychotic symptoms through dopaminergic and serotonergic receptor blockade but does not block NMDA receptors or eliminate the glutamatergic vulnerability that makes NMDA antagonists risky in patients with psychotic disorders. D2 blockade does not categorically prevent ketamine-induced psychosis.
4. A 47-year-old woman with treatment-resistant depression and pulmonary tuberculosis is receiving rifampin 600 mg daily as part of her antituberculosis regimen. She completes a course of six IV ketamine infusions at 0.5 mg/kg over 40 minutes. Her treating psychiatrist notes that while she does experience some antidepressant response after each infusion, the duration of benefit is only one to two days rather than the expected three to seven days, and her peak response is less robust than typically observed. Her vital signs, dissociative scores, and infusion tolerability are otherwise unremarkable. Which mechanism most directly explains her attenuated and shortened antidepressant response?
A) Rifampin's antimicrobial activity alters the gut microbiome, reducing enterohepatic circulation of ketamine metabolites and shortening their effective half-life, which reduces the duration of norketamine-mediated NMDA activity that normally sustains the antidepressant effect between infusions
B) Rifampin competitively inhibits ketamine's binding at the NMDA receptor channel pore by occupying the same transmembrane binding site, reducing the degree of NMDA blockade achieved at the standard antidepressant dose despite normal plasma concentrations
C) Rifampin is a potent inducer of CYP3A4 and CYP2B6, the hepatic enzymes primarily responsible for ketamine metabolism; enzyme induction accelerates ketamine's conversion to norketamine, reducing peak plasma ketamine concentrations and the area under the concentration-time curve after a standard weight-based dose, thereby reducing the degree and duration of NMDA receptor occupancy and attenuating the downstream antidepressant cascade
D) Rifampin induces P-glycoprotein at the blood-brain barrier, reducing CNS penetration of ketamine such that brain concentrations are insufficient to trigger the disinhibition-synaptogenesis cascade even when plasma levels appear normal on standard pharmacokinetic monitoring
E) The shortened antidepressant response reflects rifampin's direct anti-BDNF effect: rifampin inhibits BDNF gene transcription in prefrontal cortical neurons, reducing the availability of BDNF for ketamine-triggered TrkB activation and thereby shortening the duration of mTORC1-dependent synaptogenesis
ANSWER: C
Rationale:
Ketamine undergoes hepatic N-demethylation primarily via CYP3A4 and CYP2B6 to produce norketamine. Rifampin is one of the most potent inducers of both CYP3A4 and CYP2B6 available in clinical medicine, and its induction of these enzymes is well established as a source of clinically significant pharmacokinetic drug interactions. In a patient receiving rifampin, hepatic CYP3A4 and CYP2B6 activity is substantially upregulated, accelerating ketamine's conversion to norketamine and increasing the rate of overall drug clearance. The consequence is reduced peak plasma ketamine concentrations (Cmax) and a reduced area under the concentration-time curve (AUC) following a standard 0.5 mg/kg dose. Because NMDA receptor occupancy in the brain — and therefore the magnitude of the glutamate burst, AMPA activation, BDNF release, TrkB signaling, and mTORC1-dependent synaptogenesis — is determined by the plasma concentration-time profile of ketamine reaching the CNS, reduced systemic exposure directly attenuates both the magnitude and duration of the antidepressant response. The unremarkable dissociation and vital sign profile during infusion is consistent with plasma concentrations that trigger some pharmacodynamic effect but at a reduced level. Clinical management should include recognition of this interaction and consideration of dose adjustment or, preferably, substitution of the rifampin regimen with a less CYP-inducing antituberculosis agent if clinically feasible.
Option A: Option A is incorrect because ketamine does not undergo significant enterohepatic circulation, and rifampin's antimicrobial effect on the gut microbiome is not a clinically relevant mechanism for the attenuated ketamine response observed. The primary metabolic pathway for ketamine is hepatic CYP-mediated N-demethylation, not enteric recycling.
Option B: Option B is incorrect because rifampin does not have pharmacological activity at the NMDA receptor channel pore. It is an antibiotic that inhibits bacterial RNA polymerase. There is no established pharmacodynamic interaction between rifampin and the NMDA receptor at any clinically achievable rifampin concentration.
Option D: Option D is incorrect because while rifampin does induce P-glycoprotein expression at the blood-brain barrier, this mechanism is not the primary explanation for the attenuated ketamine antidepressant response. Ketamine is highly lipophilic and crosses the blood-brain barrier predominantly by passive diffusion rather than through active transport mechanisms that P-glycoprotein could meaningfully restrict at clinically relevant concentrations.
Option E: Option E is incorrect because rifampin does not have an established direct anti-BDNF effect through inhibition of BDNF gene transcription in prefrontal neurons. The attenuation of the antidepressant response in this patient is pharmacokinetic in origin, reflecting reduced ketamine plasma exposure due to CYP induction, not a downstream interference with BDNF availability.
5. A 61-year-old man with treatment-resistant depression is referred for consideration of IV ketamine therapy. His medical history is significant for a 4.8 cm abdominal aortic aneurysm that is under surveillance by vascular surgery and has not yet reached the threshold for elective repair. His blood pressure is well-controlled at 128/76 mmHg on amlodipine. His psychiatrist asks whether IV ketamine can be initiated given the well-controlled hypertension. What is the most appropriate response regarding ketamine candidacy?
A) IV ketamine can be initiated safely because his blood pressure is well-controlled at baseline; the absolute contraindication to ketamine applies only to patients with uncontrolled hypertension, and the presence of an aneurysm without active hypertension does not constitute an independent contraindication
B) IV ketamine can be initiated with the addition of a short-acting intravenous beta-blocker administered 10 minutes before each infusion to blunt the sympathomimetic pressor response and reduce the risk of aneurysm stress during the infusion period
C) IV ketamine can be initiated provided the vascular surgery team provides written clearance confirming that the aneurysm is stable and not at imminent rupture risk, as surgical clearance converts the absolute contraindication to a relative one that can be managed with enhanced monitoring
D) IV ketamine can be initiated at a lower dose of 0.25 mg/kg rather than 0.5 mg/kg to halve the sympathomimetic cardiovascular effect, which proportionally reduces the hemodynamic stress on the aneurysmal vessel wall to a clinically acceptable level
E) A known aortic aneurysm is an absolute contraindication to IV ketamine and esketamine regardless of baseline blood pressure control; ketamine's sympathomimetic effects produce transient but unpredictable blood pressure elevations with each administration that create an unacceptable risk of aneurysm rupture that cannot be mitigated by blood pressure control, prophylactic beta-blockade, dose reduction, or vascular surgery clearance
ANSWER: E
Rationale:
Aneurysmal vascular disease is an absolute contraindication to both IV ketamine and esketamine in the antidepressant setting, and this contraindication applies regardless of baseline blood pressure control. Ketamine produces sympathomimetic cardiovascular effects through inhibition of catecholamine reuptake, generating transient increases in systolic and diastolic blood pressure with each administration. The magnitude of these increases is dose-dependent and variable between individuals, and they cannot be reliably predicted or fully prevented by pre-existing antihypertensive therapy or prophylactic beta-blockade. In a patient with an aortic aneurysm, even a transient blood pressure elevation of 15 to 20 mmHg above a well-controlled baseline creates hemodynamic wall stress on the aneurysmal vessel that carries a meaningful risk of rupture or dissection. The fact that baseline blood pressure is well-controlled with amlodipine addresses the resting hemodynamic state but does not protect against the acute pressor response during drug administration. This patient should be referred back to his treatment team to explore alternative rapid-acting antidepressant strategies that do not carry sympathomimetic cardiovascular risk, such as electroconvulsive therapy, which has its own but different risk profile in this context.
Option A: Option A is incorrect because the absolute contraindication to ketamine in the setting of aneurysmal vascular disease is not conditioned on blood pressure being uncontrolled. The contraindication specifically identifies aneurysmal vascular disease as an independent absolute contraindication because of the acute pressor effect that accompanies each ketamine administration, regardless of resting blood pressure control.
Option B: Option B is incorrect because prophylactic intravenous beta-blockade does not convert the absolute contraindication to a manageable risk. While beta-blockers can attenuate ketamine's heart rate and some blood pressure effects, they do not reliably prevent the acute sympathomimetic pressor response completely, and the residual pressor effect in a patient with an aortic aneurysm remains an unacceptable risk.
Option C: Option C is incorrect because vascular surgery clearance does not convert an absolute contraindication to a relative one. The contraindication is pharmacologically grounded in ketamine's mechanism of action rather than in the specific size or stability of the aneurysm; it applies to any patient with aneurysmal vascular disease, not only those with aneurysms judged to be at imminent rupture risk.
Option D: Option D is incorrect because reducing the dose to 0.25 mg/kg does not eliminate the sympathomimetic pressor risk to a clinically acceptable level in a patient with an aortic aneurysm. Dose reduction attenuates but does not abolish the cardiovascular effects, and the absolute contraindication does not include a dose threshold below which administration becomes acceptable in the presence of aneurysmal disease.
6. A 33-year-old woman has been receiving esketamine nasal spray 84 mg twice weekly for nine months as maintenance therapy for treatment-resistant depression with excellent antidepressant response. She reports a two-month history of urinary urgency, frequency, and dysuria. A urine culture obtained by her primary care physician was negative for infection. She denies any recreational drug use. What is the most appropriate next step in evaluating her urinary symptoms?
A) Reassure the patient that ketamine-induced uropathy cannot occur with intranasal esketamine at therapeutic doses because systemic bioavailability is only 48%, meaning urothelial drug exposure is insufficient to cause the inflammatory and fibrotic changes associated with uropathy, which require intravenous administration at anesthetic doses
B) Obtain a detailed urological history including onset, severity, and progression of symptoms; confirm absence of active infection with urinalysis; and refer to urology for formal evaluation including cystometric assessment of bladder capacity, given that nine months of twice-weekly esketamine represents meaningful cumulative systemic exposure and the symptom pattern with a negative urine culture is consistent with possible esketamine-associated uropathy requiring objective characterization
C) Attribute the urinary symptoms to the concurrent oral antidepressant she takes as required by the REMS program, discontinue the oral antidepressant, and reassess urinary symptoms at a four-week follow-up visit before pursuing urological evaluation
D) Discontinue esketamine immediately and permanently because the REMS program mandates that any urinary symptom in a patient receiving esketamine constitutes grounds for immediate treatment termination and a permanent treatment ban
E) Order a computed tomography (CT) scan of the abdomen and pelvis with contrast to evaluate for ketamine-associated upper tract involvement including hydronephrosis before performing any lower urinary tract assessment, because upper tract damage precedes bladder symptoms in ketamine uropathy
ANSWER: B
Rationale:
The clinical picture — nine months of twice-weekly esketamine, a two-month history of urinary urgency, frequency, and dysuria, and a negative urine culture — warrants systematic evaluation for esketamine-associated uropathy rather than dismissal or premature action. While the risk of uropathy at clinical antidepressant doses is substantially lower than at the high doses and frequencies of recreational use, intranasal esketamine does achieve approximately 48% systemic bioavailability, meaning that at 84 mg twice weekly over nine months the patient has had repeated urothelial exposure to systemically circulating esketamine and its metabolites. The negative urine culture excludes bacterial infection as the cause and raises the probability of a drug-related etiology. The appropriate response is a systematic clinical assessment: detailed symptom history, urinalysis to confirm the absence of other urological diagnoses, and urology referral for cystometric evaluation of bladder capacity and function. This enables objective characterization of any bladder pathology and informs whether esketamine should be continued, dose-reduced, or discontinued — a decision that should incorporate the patient's excellent antidepressant response and the clinical severity of any confirmed uropathy.
Option A: Option A is incorrect because intranasal esketamine does produce meaningful systemic bioavailability of approximately 48%, and repeated exposure over nine months represents real cumulative urothelial drug exposure. The claim that the intranasal route categorically prevents uropathy is not supported and should not be used to dismiss urinary symptoms in a patient with this treatment history.
Option C: Option C is incorrect because attributing urinary urgency, frequency, and dysuria to the concurrent oral antidepressant without objective evaluation is not appropriate given the temporal pattern, negative urine culture, and established association between esketamine and bladder pathology. Both the oral antidepressant and esketamine should be considered in the differential, but dismissing esketamine as a cause without urological assessment is premature.
Option D: Option D is incorrect because the REMS program does not mandate immediate and permanent treatment termination at the first emergence of any urinary symptom. The appropriate response is clinical assessment, not reflexive discontinuation. Decisions about whether to continue, modify, or stop esketamine should be based on objective urological findings and the clinical risk-benefit assessment for this patient.
Option E: Option E is incorrect because initiating evaluation with a CT scan of the abdomen and pelvis before any lower urinary tract assessment inverts the appropriate diagnostic sequence. Bladder symptoms are the presenting complaint, and lower urinary tract evaluation including cystometry is the appropriate initial diagnostic step. Upper tract imaging for hydronephrosis would be indicated after bladder pathology is characterized and if upper tract involvement is suspected.
7. A 39-year-old man with treatment-resistant depression has just completed his esketamine nasal spray administration and the mandatory two-hour observation period at the clinic. He feels subjectively well, states that his dissociative symptoms have completely resolved, and asks whether he can drive himself home since he lives only three miles from the clinic and his scheduled ride fell through. He reports feeling "completely back to normal." What is the correct response?
A) The patient may drive himself home because the mandatory two-hour observation period has been completed, the esketamine has been cleared from plasma by this point, and the REMS program's driving restriction applies only during the active dissociative period, which he reports has resolved
B) The patient may drive if he passes a brief standardized cognitive assessment administered by clinic staff that confirms return to baseline on reaction time and executive function, as the REMS program permits driving after functional recovery regardless of time elapsed since administration
C) The patient may drive because three miles represents a de minimis distance for which the REMS program includes a proximity exception, and the risk of impaired driving over a short distance is clinically negligible compared with the logistical burden of arranging alternative transportation
D) The patient may not drive on the day of esketamine administration regardless of subjective recovery of normal function; the REMS program prohibits driving on the treatment day as an absolute requirement, and the clinic must not clear him for driving even if his dissociative symptoms have resolved and the observation period is complete — alternative transportation must be arranged
E) The patient may drive only if accompanied by a licensed adult passenger who can take over driving in the event of sudden symptom recurrence, as the REMS program permits driving after the observation period with a qualified co-pilot present
ANSWER: D
Rationale:
The esketamine REMS program prohibits driving or operating heavy machinery on the day of administration as an absolute requirement, without exception for subjective symptom resolution, distance, proximity, or completion of the two-hour observation period. This requirement reflects several pharmacological realities: sedation from esketamine can persist for several hours beyond the resolution of acute dissociative symptoms, and subjective perception of recovery does not reliably predict objective psychomotor and cognitive function; residual impairment in reaction time, divided attention, and executive function can persist even after patients report feeling normal; and the two-hour observation period is designed to ensure clinical safety before discharge, not to serve as a certification of fitness to drive. The patient's sincere belief that he has fully recovered is a well-recognized feature of sedative and dissociative drug effects — impaired insight into residual impairment is a characteristic of these drugs rather than evidence of actual recovery. The clinic must not permit driving regardless of the patient's self-assessment, and clinic staff should assist the patient in arranging alternative transportation including a rideshare service, a family member, or a taxi.
Option A: Option A is incorrect because the REMS driving prohibition is not limited to the active dissociative period; it applies to the entire day of administration. The two-hour observation period confirms clinical safety for discharge, not fitness for driving. Residual sedation and cognitive impairment can persist beyond the observable dissociative window.
Option B: Option B is incorrect because the REMS program does not include a provision for driving clearance based on performance on a brief cognitive assessment administered by clinic staff. The prohibition is categorical for the day of administration and is not subject to functional testing exceptions at the clinic level.
Option C: Option C is incorrect because the REMS program does not include a proximity exception for short driving distances. The prohibition applies regardless of the distance to the patient's destination. A three-mile drive in traffic requires the same psychomotor and cognitive function as a longer drive and is not categorically safer.
Option E: Option E is incorrect because the REMS program does not permit driving with a co-pilot after the observation period. The driving prohibition covers operating a vehicle as the driver; having a passenger present does not satisfy the REMS requirement and does not make driving permissible on the day of treatment.
8. A 52-year-old woman with treatment-resistant depression and well-controlled hypertension (baseline 134/82 mmHg on lisinopril) is 20 minutes into her third IV ketamine infusion at 0.5 mg/kg over 40 minutes. Her 15-minute vital sign check reveals a blood pressure of 168/98 mmHg and heart rate of 94 bpm. She reports mild dissociation and headache but denies chest pain, shortness of breath, visual changes, or neck stiffness. What is the most appropriate immediate management?
A) Temporarily slow or pause the ketamine infusion, reassess blood pressure and symptoms at five-minute intervals, and assess for any signs of end-organ involvement; if blood pressure decreases toward acceptable levels and no end-organ symptoms develop, the infusion may be resumed at a reduced rate with continued close monitoring, as this blood pressure elevation is within the expected range of ketamine's sympathomimetic effect and does not by itself mandate infusion termination
B) Immediately terminate the infusion and administer IV labetalol 20 mg as a bolus, because a blood pressure of 168/98 mmHg during ketamine infusion represents a hypertensive emergency requiring pharmacological intervention before any further assessment
C) Continue the infusion at the current rate without change, because blood pressure elevations during ketamine infusion are always transient and self-resolving and a reading of 168/98 mmHg is within the expected range that requires no clinical response per standard monitoring protocol
D) Immediately terminate the infusion, place the patient in the Trendelenburg position, and administer IV nitroglycerin, because the combination of elevated blood pressure and headache indicates probable hypertensive encephalopathy requiring emergency management
E) Continue the infusion and administer oral clonidine 0.1 mg to lower blood pressure, as oral antihypertensive agents are the preferred first-line intervention for blood pressure elevation during ketamine infusion per standard clinic protocol
ANSWER: A
Rationale:
A blood pressure of 168/98 mmHg at 20 minutes into a ketamine infusion, in a patient with well-controlled baseline hypertension and a headache but no symptoms or signs of end-organ involvement, represents an elevated but not emergency-level pressor response that warrants a stepwise, proportionate clinical response rather than immediate termination or emergency pharmacological intervention. The most appropriate initial step is to temporarily slow or pause the infusion — which reduces ongoing drug delivery and the catecholamine reuptake inhibition driving the pressor effect — and reassess blood pressure and symptoms at five-minute intervals. This allows the acute elevation to be characterized: if blood pressure trends down toward acceptable levels and no end-organ symptoms develop, the infusion may be carefully resumed at a reduced rate with continued close monitoring. The headache in the context of blood pressure elevation requires careful symptom assessment to exclude any signs suggesting hypertensive urgency or emergency — chest pain, visual changes, altered consciousness, or focal neurological signs — but the current symptom profile without these features does not mandate emergency management. This proportionate response balances patient safety with the possibility of completing the therapeutic infusion.
Option B: Option B is incorrect because a blood pressure of 168/98 mmHg with no signs of end-organ involvement does not meet the definition of a hypertensive emergency. Immediate IV labetalol and infusion termination without first pausing and reassessing is a disproportionate response to this blood pressure level in the absence of end-organ findings.
Option C: Option C is incorrect because continuing the infusion without any clinical response to a blood pressure of 168/98 mmHg in a patient with baseline hypertension and a headache is not appropriate. While ketamine-associated pressor responses are often self-limiting, this blood pressure level with symptoms requires active clinical reassessment and at minimum a temporary pause to assess the trajectory.
Option D: Option D is incorrect because the clinical picture described — elevated blood pressure with mild headache and intact neurological status, no papilledema, no focal deficits, no altered consciousness — does not indicate hypertensive encephalopathy. Trendelenburg positioning and emergency IV nitroglycerin are inappropriate for this clinical scenario and represent a significant overreaction to the presented findings.
Option E: Option E is incorrect because oral clonidine is not the appropriate intervention for blood pressure management during an active IV infusion. Oral agents have delayed onset unsuitable for managing a pressor response occurring during an infusion, and continuing the infusion while waiting for oral medication to take effect does not address the ongoing sympathomimetic stimulus. The primary intervention is to modify or pause the infusion.
9. A 41-year-old woman has had treatment-resistant depression for six years. Her most disabling symptom is profound anhedonia — she derives no pleasure from food, social interaction, music, or activities she formerly enjoyed. She has failed four adequate antidepressant trials including two SSRIs, an SNRI, and bupropion. After her first IV ketamine infusion, she calls her psychiatrist 18 hours later to report that for the first time in years she enjoyed a meal and laughed at a television program. Her overall mood remains depressed but the hedonic capacity has partially returned. Her psychiatrist wants to explain to her why ketamine specifically addressed anhedonia when four monoamine-based agents did not. Which mechanistic explanation most directly accounts for this clinical observation?
A) Ketamine reversed the anhedonia by blocking serotonin reuptake more potently than the SSRIs she had previously tried; as the most potent serotonin reuptake inhibitor currently available, ketamine achieves synaptic serotonin concentrations sufficient to restore hedonic signaling in circuits that had been unresponsive to lower-potency reuptake inhibitors
B) Ketamine's reversal of anhedonia reflects its opioid receptor agonist properties in the nucleus accumbens; the partial mu-opioid receptor activation by ketamine directly increases dopamine release in reward circuits through a mechanism that SSRIs, SNRIs, and bupropion cannot replicate because none of them engage opioid receptors
C) The lateral habenula, which encodes aversive outcomes and pathologically suppresses dopamine release in the nucleus accumbens in depression through NMDA-dependent burst firing, was disinhibited by ketamine's NMDA receptor blockade; the resulting restoration of dopaminergic tone in reward circuitry produced rapid hedonic recovery through a pathway that SSRIs, SNRIs, and bupropion do not directly engage
D) Bupropion is a dopamine and norepinephrine reuptake inhibitor that should have addressed the dopaminergic deficit driving anhedonia; the fact that bupropion also failed suggests that the anhedonia has a structural rather than functional basis and that ketamine's effect is temporary neuroplasticity that will not be sustained without repeated infusions
E) Ketamine reversed the anhedonia through direct activation of dopamine D1 receptors in the prefrontal cortex, bypassing the nucleus accumbens reward circuit entirely; this cortical dopaminergic mechanism is independent of the lateral habenula and is the primary pathway through which ketamine addresses anhedonia in patients unresponsive to monoamine-based treatments
ANSWER: C
Rationale:
The lateral habenula (LHb) mechanism provides the most direct and pharmacologically grounded explanation for ketamine's specific effectiveness in reversing anhedonia that has been unresponsive to monoamine-based antidepressants. In depression, pathological NMDA-dependent burst firing in LHb neurons tonically suppresses dopamine release from ventral tegmental area neurons projecting to the nucleus accumbens, producing the motivational deficits and inability to experience pleasure that characterize anhedonia. SSRIs, SNRIs, and bupropion act on monoamine reuptake transporters — serotonin transporter, norepinephrine transporter, and dopamine transporter respectively — and their therapeutic effects develop slowly through receptor adaptations over weeks. None of these agents directly suppresses LHb burst firing or acutely disinhibits the dopaminergic reward circuit through the NMDA-dependent mechanism that ketamine employs. Ketamine's NMDA blockade on LHb neurons rapidly suppresses their burst firing within hours of infusion, releasing the dopaminergic brake and restoring hedonic function through a pathway that is inaccessible to reuptake inhibitors. The 18-hour return of hedonic capacity is temporally consistent with the downstream cascade of LHb disinhibition and dopaminergic reward circuit restoration, which occurs within hours and outlasts the drug's plasma half-life.
Option A: Option A is incorrect because ketamine is not a serotonin reuptake inhibitor. Its primary mechanism is NMDA receptor blockade. Describing ketamine as the most potent SSRI available is pharmacologically inaccurate and does not account for the hedonic recovery, which is mediated through dopaminergic reward circuit disinhibition via the LHb pathway, not serotonergic reuptake inhibition.
Option B: Option B is incorrect because while opioid receptor interactions of ketamine have been investigated as contributing to antidepressant mechanisms, the established primary mechanism for rapid reversal of anhedonia is the lateral habenula NMDA blockade and dopaminergic reward circuit disinhibition. Characterizing this as partial mu-opioid receptor agonism in the nucleus accumbens is not the established mechanistic framework for this clinical phenomenon.
Option D: Option D is incorrect because bupropion's failure does not establish a structural basis for the anhedonia or predict that ketamine's effect will be unsustained. Bupropion blocks dopamine and norepinephrine reuptake transporters, which is a functionally different mechanism from the LHb-mediated circuit-level dopaminergic disinhibition produced by ketamine. The failure of transporter blockade does not predict failure of circuit-level disinhibition.
Option E: Option E is incorrect because ketamine does not reverse anhedonia through direct activation of dopamine D1 receptors in the prefrontal cortex. Ketamine is an NMDA antagonist, not a dopamine receptor agonist. The mechanism for anhedonia reversal involves NMDA blockade in the lateral habenula and downstream dopaminergic circuit disinhibition through the nucleus accumbens, not direct cortical dopamine receptor activation.
10. A 29-year-old man with treatment-resistant depression is being evaluated for esketamine therapy. During the psychiatric intake, he discloses that he used ketamine recreationally at parties approximately 20 times over a three-year period ending two years ago, never developing physical dependence or requiring treatment. He has been abstinent from all recreational substances for two years and is engaged with an outpatient addiction medicine counselor. He meets the diagnostic criteria for treatment-resistant depression and has failed three adequate antidepressant trials. How should his recreational ketamine history inform the clinical decision about esketamine candidacy?
A) A history of recreational ketamine use is a formal absolute contraindication listed in the esketamine FDA prescribing information, and the patient is categorically ineligible for esketamine regardless of the duration of his abstinence or his current clinical presentation
B) The recreational ketamine history is clinically irrelevant to esketamine candidacy because esketamine is a different enantiomer from the racemic ketamine used recreationally, and patients with a history of racemic ketamine use have no established cross-sensitivity or increased risk of psychological dependence with the S-enantiomer
C) The patient should receive esketamine at double the standard dose to compensate for presumed tolerance at the NMDA receptor from his prior recreational use, which would otherwise result in a subtherapeutic antidepressant response at standard doses
D) The recreational history is irrelevant because the REMS program's clinic-administration and no-take-home requirements eliminate all abuse risk for patients receiving esketamine, making prior recreational use history immaterial to the safety assessment
E) The recreational ketamine history is a clinically significant risk factor that warrants careful consideration and ideally addiction medicine consultation; most centers require closer supervision and some exclude patients with a history of ketamine or phencyclidine abuse from esketamine programs, though his two-year abstinence and ongoing addiction support are favorable factors that inform but do not automatically determine candidacy
ANSWER: E
Rationale:
A history of recreational ketamine or phencyclidine use is a clinically significant risk factor for esketamine candidacy that requires individualized assessment rather than categorical inclusion or exclusion. Esketamine is a Schedule III controlled substance with established abuse and psychological dependence potential, and a patient with a prior history of ketamine abuse has demonstrated behavioral vulnerability to its reinforcing properties at doses producing dissociation and euphoria. Most certified esketamine treatment centers treat this history as a meaningful risk factor requiring additional clinical scrutiny, and some centers exclude patients with a personal history of ketamine or phencyclidine abuse entirely from their programs. The appropriate response in this case is neither automatic eligibility nor automatic exclusion. The patient's two-year abstinence, absence of physical dependence, current engagement with addiction medicine, and three prior failed antidepressant trials are all clinically relevant favorable factors. The clinical team — ideally in consultation with the addiction medicine provider already involved in the patient's care — should assess whether the benefit of esketamine treatment in this patient with established TRD outweighs the risk of relapse to recreational use, and should establish an enhanced monitoring plan if treatment proceeds.
Option A: Option A is incorrect because a history of recreational ketamine use is not listed as a formal absolute contraindication in the esketamine FDA prescribing information in the same category as aneurysmal vascular disease or intracerebral hemorrhage. The prescribing information describes the need for caution in patients with a history of substance abuse, not categorical ineligibility.
Option B: Option B is incorrect because the S-enantiomer versus racemic mixture distinction does not eliminate the clinical significance of a prior recreational ketamine history. Esketamine is the more potent NMDA antagonist enantiomer and is at least as likely to have abuse potential as racemic ketamine. The enantiomeric difference does not constitute a pharmacological basis for dismissing the prior use history as irrelevant.
Option C: Option C is incorrect because recreational ketamine use does not reliably produce pharmacodynamically meaningful NMDA receptor tolerance at the antidepressant doses used clinically. Doubling the standard dose in a patient with a recreational use history is not a validated clinical practice and introduces unnecessary risk.
Option D: Option D is incorrect because while the REMS program's clinic-administration requirements substantially reduce diversion and home-misuse risk, they do not eliminate the risk of psychological reinforcement or craving in a patient with established behavioral vulnerability to ketamine's dissociative and rewarding properties. Prior recreational use history remains clinically meaningful even within a supervised administration context.
11. A 50-year-old woman with treatment-resistant depression has achieved full remission after four months of esketamine nasal spray combined with sertraline. She feels well and asks her psychiatrist whether she can stop the sertraline, which she finds causes mild nausea, while continuing the esketamine maintenance sessions. She reasons that since the esketamine seems to be "doing the work," she would prefer to simplify her regimen. What is the most appropriate response?
A) The patient may stop sertraline and continue esketamine as monotherapy because the REMS program's requirement for concurrent oral antidepressant applies only during the induction phase; once maintenance remission is established, esketamine monotherapy is permitted under the approved labeling
B) The patient may substitute sertraline with a lower-dose tricyclic antidepressant that has less nausea as a side effect, which satisfies the oral antidepressant requirement of the REMS program while addressing the tolerability concern
C) The concurrent oral antidepressant is a requirement of both the FDA-approved labeling and the REMS program and applies throughout the treatment course including maintenance; esketamine is not approved for use as monotherapy at any phase of treatment, and the appropriate response is to address the sertraline-related nausea through dose adjustment, timing modification, or substitution with a better-tolerated oral antidepressant rather than discontinuation
D) The patient may discontinue sertraline because the combination therapy is now redundant; esketamine's mTORC1-dependent synaptogenesis has produced structural synaptic changes that permanently replace the function that the oral antidepressant was previously providing, and maintenance oral antidepressant is not required once structural remission is established
E) The concurrent oral antidepressant can be discontinued at the physician's discretion once the patient has maintained remission for at least six consecutive months, as the REMS program includes a remission-duration exception that permits esketamine monotherapy after this threshold is reached
ANSWER: C
Rationale:
The requirement for concurrent oral antidepressant use with esketamine is embedded in the FDA-approved labeling and REMS program and applies throughout the entire treatment course, including the maintenance phase. Esketamine is not approved for use as monotherapy at any point in treatment, and the concurrent oral antidepressant is not optional once remission is achieved. The pharmacological rationale is that esketamine's effect is transient — its antidepressant effect wanes over days without repeated dosing, and the oral antidepressant provides the sustained, continuously maintained pharmacotherapy required between esketamine administrations and, critically, after any eventual tapering or discontinuation of esketamine. Stopping sertraline while continuing esketamine would remove this maintenance backbone from the patient's regimen and place esketamine in a monotherapy role for which it does not have regulatory approval. The clinically appropriate response is to address the nausea tolerability concern through practical measures: taking sertraline with food, switching to evening dosing, reducing the sertraline dose if clinically acceptable, or substituting sertraline with a better-tolerated oral antidepressant from a different class — all of which maintain the concurrent oral antidepressant requirement while resolving the tolerability issue.
Option A: Option A is incorrect because the concurrent oral antidepressant requirement is not limited to the induction phase. It applies to every administration throughout the treatment course, and there is no approved labeling provision that permits esketamine monotherapy during maintenance once remission is established.
Option B: Option B is incorrect in its conclusion about substituting to a lower-dose tricyclic antidepressant, but the underlying principle that sertraline could be replaced with a different tolerable oral antidepressant rather than discontinued is clinically sound. However, the question asks for the most appropriate response, which is option C because it explicitly addresses the monotherapy prohibition and frames the solution as addressing tolerability while maintaining the required concurrent oral antidepressant.
Option D: Option D is incorrect because the structural synaptic changes produced by ketamine's mTORC1-dependent synaptogenesis are real but transient, waning over days to weeks without continued treatment. They do not constitute a permanent replacement for the pharmacological function of the oral antidepressant, and "structural remission" is not an established clinical concept that permits withdrawal of maintenance pharmacotherapy.
Option E: Option E is incorrect because the REMS program does not include a remission-duration exception permitting esketamine monotherapy after any defined period of maintained remission. The concurrent oral antidepressant requirement has no time-limited exception based on remission duration.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.